Melatonin for the prevention and treatment of jet lag Herxheimer A, Petrie kj



Yüklə 194,99 Kb.

səhifə4/7
tarix20.09.2017
ölçüsü194,99 Kb.
1   2   3   4   5   6   7

All three trials of the 'pre+post' regimen in civilian travellers found less jet-lag and better sleep 

quality in the melatonin group. In the trial in soldiers, melatonin helped circadian adaptation and 

maintained sleep durations of 7-8 hours at the destination, while on placebo sleep was 5-7 hours. In 

cognitive tests done soon after waking, the melatonin group made about half as many errors as the 

placebo group. Symptoms of jet-lag were not directly assessed.  

Of the four trials of the 'post' regimen, 98 Suhner (a) found that melatonin very clearly improved 

self-rated sleep quality, shortened sleep latency and reduced fatigue and daytime sleepiness. Two 

other trials found trends in the same direction that either did not reach statistical significance (92 

Nickelsen) or are not adequately reported (98 Suhner b). 97 Spitzer found no differences between the 

treatment groups, most likely because the participants' baseline rhythms had not adapted to the time 

zone from which they left.  

These data suggest that the 'pre+post' regimens have no important advantage over 'post' regimens 

that might outweigh the inconvenience of dosing before the day of travel, but they have not been 

directly compared in ordinary travellers.  

Comparison (3): eastward flights v. westward flights 

Two trials have compared eastward with westward flights as a part of their design. The Auckland - 

London trial (89 Petrie) did so, but is not suitable for this comparison as the travellers crossed 12 

time zones and it takes over 24 hours to complete the journey. Nickelsen's volunteers flew from 

Frankfurt to North America, returning at least 2 weeks later; they did not cross over. In this study jet-

lag was worse after the eastward flight (overall VAS, combining results with melatonin and 

withplacebo : eastward 5.9, westward 3.0). Jet-lag scores were modestly lower on melatonin than on 

placebo in both directions.  

Comparison (4): passengers v. airline staff  

Seven of the 8 trials were in travellers, one in airline cabin crew (93 Petrie). Both groups showed 

some benefit from melatonin, but their duties and activities at the destination differed. For the 

travellers these were undefined and very diverse. The airline cabin crew entered the trial with very 

disordered circadian rhythms, and this probably made it harder to achieve and detect any 

improvement in jet-lag. Even so a benefit was shown.  

Comparison (5a): low doses (5mg or less) v. high (8mg or more) 

One trial, that of Claustrat, compared melatonin 8mg with placebo. Nothing in the results of this trial 

suggests a greater effect than was seen with lower dosage.  

Comparisons (5b, 5c): low doses v. very low doses (0.5mg): rapid-release melatonin v. slow-release 

melatonin 

Suhner (a) compared doses of 5mg and 0.5mg in ordinary (fast-release tablets) and 2mg in a slow-

release tablet. The 5mg dosage improved self-rated sleep quality, shortened sleep latency, and 

reduced fatigue and daytime sleepiness after intercontinental flight. The lower dosage of 0.5mg was 

almost as effective; only the hypnotic properties of melatonin, sleep quality and sleep latency were 

greater with the 5mg dosage. 

The 2mg slow-release form was less effective than either of the fast-release tablets.  

Comparison (6): short (48 hr or less) v. long (over 48 hr) treatment 

All nine trials were of treatment for longer than 2 days; none examined a treatment duration of two 

days or less.  

Reported symptoms/ side effects 

Eight RCT reports note symptoms, but only Suhner's two studies looked for symptoms 

systematically. The first (Suhner a) found no statistically significant differences in the incidence of 

symptoms between melatonin and placebo. Some symptoms - daytime sleepiness, dizziness, 

headache and loss of appetite - were most frequent on day 1 after the flight and became less frequent 



on the next 3 days of treatment; these were probably symptoms of jet-lag. In Suhner (b) the 

zolpidem+melatonin group felt significantly sleepier in the morning, while the melatonin group felt 

least sleepy. The combination group also felt significantly more confused and more nauseated than 

all other treatment groups. Ear/ nose/ throat problems were most frequent in melatonin users; 

pruritus was least frequent in this group. 

Most adverse events or symptoms in the other six studies can be regarded as no more than sketchy 

qualitative pointers. However, hypnotic effects after melatonin occurred in 5 of the studies, affecting 

about 10% of the participants. Others included headache or 'heavy head' (2 studies), disorientation 

(88 Arendt), nausea, and gastrointestinal problems. One individual experienced difficulty in 

swallowing and breathing within 20 minutes of taking the first dose of 0.5mg melatonin, symptoms 

which subsided after 45 minutes (98 Spitzer). This person stopped taking the capsules, but agreed to 

take another single dose on another occasion to see if the symptoms would recur. They did, but were 

somewhat milder. All the adverse events reported in the trials occurred during treatment and appear 

to have been short-lived.  

Reports of adverse effects from sources other than clinical trials 

Table 02


 

Potentially relevant adverse events have been reported (from sources other than clinical trials in jet-

lag) in 6 published papers and 19 unpublished case records from the WHO Uppsala Monitoring 

Centre (UMC). The reports obtained from the website of the US FDA SN/AEMS lacked essential 

details and could not be used. Table 2 lists the 25 single cases by the systems affected - CNS, 

circulation, blood clotting, skin. (Cases identified only by a number and a country are from the UMC 

register.) Many of the reports do not state whether or not the individual concerned was healthy, or 

for what purpose melatonin had been taken.  

The reports that are in our view worth noting by potential users of melatonin are marked with an 

asterisk. They concern people with epilepsy, patients taking warfarin or another oral anticoagulant, 

and anyone getting a skin rash after using melatonin.  

Four types of events that may signal a true effect of melatonin deserve investigation. Possible effects 

on mental function, sleep, seizure activity, and the circulation are complex, likely to vary greatly 

with circadian phases, and will be difficult to elucidate. The simplest possibility to study, and 

perhaps the most urgent, is that melatonin potentiates warfarin. The reports of fixed drug eruption, an 

allergic manifestation, appear be convincing and must be taken seriously.  



Discussion    

Nine of the ten trials found that melatonin taken close to bedtime at the destination decreased jet-lag 

from journeys crossing five or more time zones. The one study that did not (98 Spitzer) was 

handicapped by starting from an inappropriate baseline. No differences were detected between daily 

doses of 0.5 and 5mg melatonin, except that people fall asleep faster and sleep better after 5mg than 

0.5mg. A higher dose (92 Claustrat) is not clearly more effective than 5mg. The relative 

ineffectiveness of 2mg slow-release melatonin (98 Suhner a) suggests that a pulse of melatonin

briefly giving a higher concentration in the blood, works better.  

The effect on jet lag shown in the meta-analysis is striking. The benefit is likely to be even greater 

for flights across more time zones, but less for westward flights. 

No trials have directly assessed the use of melatonin with other strategies for reducing jet-lag, but an 

additive effect would seem likely. Light exposure and light avoidance at the destination have to be 

scheduled appropriately in order to support the adaptation process to the new time zone. This 

schedule depends on the number of time zones crossed and the direction of flight. Tables and 

computer progarmmes exist that give guidelines when to seek and when to avoid light. Furthermore, 

the rapid adoption of the new daily pattern at the traveller's destination in terms of meal times, 

exercise and sleep periods will also aid overall adaptation. The value of melatonin to travellers using 

sensible re-entrainment principles needs to be established in future research. The effects of caffeine 





Dostları ilə paylaş:
1   2   3   4   5   6   7


Verilənlər bazası müəlliflik hüququ ilə müdafiə olunur ©genderi.org 2019
rəhbərliyinə müraciət

    Ana səhifə